Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

Affiliations

• ¹ a Department of Lyphoma/Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
• ² b Department of Lymphoma , Memorial Sloan Kettering Cancer Center , New York , NY , USA.
• ³ c Department of Medical Oncology , Thomas Jefferson Medical College , Philadelphia , PA , USA.
• ⁴ f Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
• ⁵ d Department of Stem Cell Transplantation and Cellular Therapy , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
• ⁶ e Department of Hematopathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.